Defining the susceptibility of colorectal cancers to BH3-mimetic compounds
AuthorLuo, M-J; Palmieri, M; Riffkin, CD; Sakthianandeswaren, A; Djajawi, TM; Hirokawa, Y; Shuttleworth, V; Segal, DH; White, CA; Nhu, D; ...
Source TitleCell Death and Disease
University of Melbourne Author/sPalmieri, Michelle; Sieber, Oliver; Lessene, Guillaume; Gibbs, Peter; Huang, David; White, Christine; Sakthianandeswaren, Anuratha; Segal, David; Luo, Mingjie; Riffkin, Chris; ...
AffiliationMedical Biology (W.E.H.I.)
Document TypeJournal Article
CitationsLuo, M. -J., Palmieri, M., Riffkin, C. D., Sakthianandeswaren, A., Djajawi, T. M., Hirokawa, Y., Shuttleworth, V., Segal, D. H., White, C. A., Nhu, D., Lessene, G., Lee, M., Gibbs, P., Huang, D. C. S., Sieber, O. M. & Gong, J. -N. (2020). Defining the susceptibility of colorectal cancers to BH3-mimetic compounds. CELL DEATH & DISEASE, 11 (9), https://doi.org/10.1038/s41419-020-02815-0.
Access StatusOpen Access
Novel targets are required to improve the outcomes for patients with colorectal cancers. In this regard, the selective inhibitor of the pro-survival protein BCL2, venetoclax, has proven highly effective in several hematological malignancies. In addition to BCL2, potent and highly selective small molecule inhibitors of its relatives, BCLxL and MCL1, are now available, prompting us to investigate the susceptibility of colorectal cancers to the inhibition of one or more of these pro-survival proteins. While targeting BCLxL, but not BCL2 or MCL1, on its own had some impact, most (15/17) of the immortalized colorectal cancer cell lines studied were efficiently killed by the combined targeting of BCLxL and MCL1. Importantly, these in vitro findings were confirmed in a xenograft model and, interestingly, in all (5/5) patient derived tumor organoids evaluated. Our results lend strong support to the notion that BCLxL and MCL1 are highly promising targets for further evaluation in efforts to improve the treatment of colorectal cancers.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References